Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
AEterna Zentaris
(NASDAQ:AEZS)
Intraday
$1.87
-0.085
[-4.35%]
After-Hours
$1.87
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.87
-0.085
[-4.35%]
At close: Apr 22
$1.87
0
[0.00%]
PreMarket: 8:18AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for AEterna Zentaris Stock (NASDAQ:AEZS)
AEterna Zentaris Stock (NASDAQ: AEZS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 27, 2024
AEterna Zentaris: Q4 Earnings Insights
Benzinga Insights
-
Mar 27, 2024, 9:10AM
AEterna Zentaris Q4 2023 GAAP EPS $(1.16) Misses $(0.97) Estimate, Sales $100.000K Down From $2.485M YoY
Benzinga Newsdesk
-
Mar 27, 2024, 8:10AM
Aeterna Zentaris Completes Enrollment In Ongoing Pivotal DETECT-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency
Benzinga Newsdesk
-
Mar 27, 2024, 8:07AM
Tuesday, March 12, 2024
Aeterna Zentaris, Ceapro Merger Approved by Securityholders At Special Meetings
Benzinga Newsdesk
-
Mar 12, 2024, 2:13PM
Thursday, December 14, 2023
Aeterna Zentaris Inks Pact With Ceapro To Create a Diversified Biopharmaceutical Company; Transaction Expected To Close In Q1 2024
Benzinga Newsdesk
-
Dec 14, 2023, 7:54AM
Aeterna Zentaris Shares Were Halted Ahead Of News
Charles Gross
-
Dec 14, 2023, 7:52AM
Monday, November 13, 2023
HC Wainwright & Co. Maintains Buy on AEterna Zentaris, Lowers Price Target to $15
Benzinga Newsdesk
-
Nov 13, 2023, 11:23AM
Thursday, November 09, 2023
AEterna Zentaris Q3 EPS $(0.85) Misses $(0.61) Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 8:20AM
Thursday, October 05, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Oct 5, 2023, 1:22PM
Thursday, August 10, 2023
HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target
Benzinga Newsdesk
-
Aug 10, 2023, 7:47AM
Wednesday, August 09, 2023
AEterna Zentaris Q2 EPS $(0.52) Beats $(0.87) Estimate, Sales $2.25M Beat $1.14M Estimate
Benzinga Newsdesk
-
Aug 9, 2023, 8:10AM
Friday, July 14, 2023
HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target
Benzinga Newsdesk
-
Jul 14, 2023, 6:14AM
Thursday, July 13, 2023
Aeterna Zentaris Says Encouraged By Progress Across All Of Its Active Development Programs
Benzinga Newsdesk
-
Jul 13, 2023, 7:34AM
Friday, May 12, 2023
HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target
Benzinga Newsdesk
-
May 12, 2023, 7:03AM
Tuesday, May 09, 2023
AEterna Zentaris Q1 EPS $(0.88) Beats $(1.07) Estimate, Sales $2.10M Beat $900.00K Estimate
Happy Mohamed
-
May 9, 2023, 5:18PM
Monday, April 10, 2023
HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target
Benzinga Newsdesk
-
Apr 10, 2023, 6:20AM
Wednesday, April 05, 2023
Aeterna Zentaris Says US Sales Of Macrilen For Adult Use Will Be Temporarily Discontinued As Of May 23 Until Relaunch With An Alternate Commercialization Partner
Benzinga Newsdesk
-
Apr 5, 2023, 7:58AM
Friday, March 31, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Mar 31, 2023, 11:46AM
Tuesday, March 28, 2023
HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target
Benzinga Newsdesk
-
Mar 28, 2023, 6:31AM
Thursday, March 23, 2023
AEterna Zentaris Q4 Sales $2.50M Beat $1.06M Estimate
Bill Haddad
-
Mar 23, 2023, 8:13AM
Thursday, March 16, 2023
Pharmanovia To Acquire License To GHRYVELIN From Aeterna Zentaris' Existing Licensee, Consilient Health, Effective Immediately
Benzinga Newsdesk
-
Mar 16, 2023, 8:10AM
Tuesday, January 17, 2023
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19
Vandana Singh
-
Jan 17, 2023, 12:53PM
Aeterna Zentaris Will Not Pursue Further Development Of Vaccine Platform For Either COVID-19 Or Chlamydia
Benzinga Newsdesk
-
Jan 17, 2023, 8:07AM
Thursday, November 03, 2022
AEterna Zentaris: Q3 Earnings Insights
Benzinga Insights
-
Nov 3, 2022, 9:21AM
AEterna Zentaris Q3 EPS $(0.70) Down From $(0.25) YoY
Benzinga Newsdesk
-
Nov 3, 2022, 8:25AM
Monday, August 29, 2022
Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk
Benzinga Newsdesk
-
Aug 29, 2022, 8:06AM
Thursday, August 04, 2022
Aeterna Zentaris Shares Resume Trade
Bill Haddad
-
Aug 4, 2022, 2:07PM
Aeterna Zentaris Shares Halted On Circuit Breaker
Bill Haddad
-
Aug 4, 2022, 2:02PM
Wednesday, August 03, 2022
AEterna Zentaris Q2 EPS $(0.87) Down From $(0.50) YoY
Benzinga Newsdesk
-
Aug 3, 2022, 6:00PM
Aeterna Zentaris Shares Resume Trading, Up 12%
Benzinga Newsdesk
-
Aug 3, 2022, 3:40PM
Wednesday, July 20, 2022
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Lisa Levin
-
Jul 20, 2022, 3:59AM
Tuesday, July 19, 2022
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jul 19, 2022, 12:04PM
IBM And 20 Stocks Moving Premarket
Lisa Levin
-
Jul 19, 2022, 6:39AM
Monday, July 18, 2022
Boeing And 24 Stocks Moving Premarket
Lisa Levin
-
Jul 18, 2022, 6:23AM
Friday, July 15, 2022
Aeterna Zentaris Announces Shareholder Approval Of Share Consolidation
Benzinga Newsdesk
-
Jul 15, 2022, 4:17PM
Friday, July 08, 2022
Twitter And 20 Stocks Moving Premarket
Lisa Levin
-
Jul 8, 2022, 6:33AM
Friday, July 01, 2022
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Lisa Levin
-
Jul 1, 2022, 4:52AM
Thursday, June 30, 2022
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jun 30, 2022, 12:03PM
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Lisa Levin
-
Jun 30, 2022, 4:55AM
Friday, June 17, 2022
21 Stocks Moving in Friday's Pre-Market Session
Lisa Levin
-
Jun 17, 2022, 5:51AM
Wednesday, June 15, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Jun 15, 2022, 12:22PM
Wednesday, May 25, 2022
Aeterna Zentaris' Licensing Partner, Consilient Health Announces European Launch Of Ghryvelin For Diagnosing Adult Growth Hormone Deficiency
Benzinga Newsdesk
-
May 25, 2022, 8:08AM
Tuesday, May 17, 2022
73 Biggest Movers From Yesterday
Lisa Levin
-
May 17, 2022, 4:49AM
Thursday, May 12, 2022
Aeterna Zentaris Provides Update On Pre-Clinical Results From Aim Biologicals Development Program For The Potential Treatment Of Parkinson's Disease
Benzinga Newsdesk
-
May 12, 2022, 8:18AM
Wednesday, May 11, 2022
Recap: AEterna Zentaris Q1 Earnings
Benzinga Insights
-
May 11, 2022, 8:26AM
AEterna Zentaris Q1 EPS $(0.02), Same YoY
Benzinga Newsdesk
-
May 11, 2022, 8:06AM
34 Stocks Moving in Wednesday's Pre-Market Session
Lisa Levin
-
May 11, 2022, 7:05AM
Friday, May 06, 2022
24 Stocks Moving in Friday's Pre-Market Session
Lisa Levin
-
May 6, 2022, 6:11AM
Monday, April 25, 2022
Aeterna Zentaris Abstract Accepted For Presentation At IMMUNOLOGY2022 Annual Event Of the American Association Of Immunologists
Benzinga Newsdesk
-
Apr 25, 2022, 8:10AM
Tuesday, April 19, 2022
Aeterna Zentaris Reports Secured New European Patent For Use Of Macimorelin For Diagnosis Of Growth Hormone Deficiency In Adults
Benzinga Newsdesk
-
Apr 19, 2022, 8:07AM
Show more